Advertisement
UK markets close in 4 hours 12 minutes

  • FTSE 100

    8,085.43
    +40.62 (+0.50%)
     

  • FTSE 250

    19,798.60
    -1.12 (-0.01%)
     

  • AIM

    754.77
    -0.10 (-0.01%)
     

  • GBP/EUR

    1.1638
    +0.0010 (+0.08%)
     

  • GBP/USD

    1.2440
    -0.0013 (-0.10%)
     

  • Bitcoin GBP

    53,385.71
    +184.89 (+0.35%)
     

  • CMC Crypto 200

    1,434.85
    +10.75 (+0.76%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.76
    -0.60 (-0.72%)
     

  • GOLD FUTURES

    2,327.80
    -14.30 (-0.61%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,193.54
    +55.89 (+0.31%)
     

  • CAC 40

    8,133.31
    +27.53 (+0.34%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Australia competition watchdog takes GlaxoSmithKline, Novartis units to court

Reuters - UK Focus

Dec (Shanghai: 600875.SS - news) 6 (Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (Other OTC: GLAXF - news) and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.

The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated".

"We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said. (Reporting by Susan Mathew in Bengaluru)